2nd Pharma, Pricing & Marketing Access 2016 covers topics such as:
- EU and US policy challenges for market access: Stepping ahead
- Preparing your best market access strategy
- Current & future - Challenges & opportunities in pharma pricing, reimbursement & market access
- Opportunity to expose and address the market access challenges facing the industry
- Measurement strategies through to in-depth knowledge regarding payer formulary coverage trends
- Improving patient and market access through the development of targeted value propositions, comprehensive contract assessment
- Payers’ perspective
- How can payers and industry work together to ensure that innovative and valuable treatments make it to the market?
- Creating a robust patient services and reimbursement support program for biosimilar products
- Advocating and collaborating with payers for value in a new era
- How price affects market access and learn on how to set prices for optimal access and returns
- Prioritising Patients! - Adding value through an innovative patient-centered approach
- Evidence Generation - The strategic rigor and creativity applied to evidence generation
- New drugs are failing to gain reimbursement from payers/HTAs at an alarming rate, despite being approved by regulators
- Risk-sharing reimbursement models and value based pricing
- Impact of social media and digital analytics
- How to use the data sources and observational research for effective safety analysis
- Patient engagement and adherence within the environment
- New medicine introduction in developing world & overcoming challenges
- Dwell ahead of regulatory developments & improving your strategies in a cost effective way in EU, US
2nd Pharma, Pricing & Marketing Access 2016 brings together pharmaceutical, biotechnology and regulatory representatives such as:
- Reimbursement
- Pricing
- Commercial Pricing
- Market Access
- Health Economics
- Pricing Strategists
- Regulatory Affairs
- Outcomes Research
- Public Affairs
- Governmental Affairs
- Operations
- Public Policy Directors
- Regulatory bodies
- Governmental bodies
